Fluorescence endoscopy and photodynamic therapy

Digestive and Liver Disease

Volumn 34, Issue 10, 2002, Pages 754-761

  Messmann, H ^a   Endlicher, E ^a   Gelbmann, C M ^a   Scholmerich J ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Fluorescence endoscopy; Malignant lesions; Photodynamic therapy

Indexed keywords

AMINOLEVULINIC ACID; COLLAGEN; ELASTIN; OMEPRAZOLE; PHOTOFRIN; PHOTOSENSITIZING AGENT; PORPHYRIN; QUERCETIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; STEROID; UNCLASSIFIED DRUG;

ARTICLE; BARRETT ESOPHAGUS; BILE DUCT CANCER; CAMERA; CANCER PALLIATIVE THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; DRUG ACCUMULATION; DRUG UPTAKE; EARLY CANCER; EPITHELIUM DYSPLASIA; ESOPHAGUS CANCER; FLUORESCENCE; FLUORESCENCE ENDOSCOPY; FLUORESCENCE SPECTROSCOPY; FLUOROPHORE; GASTROENTEROLOGY; GASTROINTESTINAL ENDOSCOPY; HUMAN; INOPERABLE CANCER; LIGHT; MALIGNANT NEOPLASTIC DISEASE; MUCOSA; NEODYMIUM LASER; NONHUMAN; PHOTODYNAMIC THERAPY; PRECANCER; RADIATION DOSE FRACTIONATION; SIDE EFFECT; STOMACH CANCER; TISSUE DISTRIBUTION; TREATMENT INDICATION; ULCERATIVE COLITIS; UROLOGY;

EID: 0036807926     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1590-8658(02)80028-7     Document Type: Article

References (61)

1. Bond JH. Colorectal surveillance for neoplasia: an overview. Gastrointest Endosc 1999;49:35-40.
2. Sampliner RE. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 1998;93:1028-32.
3. McArdle JE, Lewin KJ, Randall G, Weinstein W. Distribution of dysplasia and early invasive carcinoma in Barrett's esophagus. Hum Pathol 1992;23:479-82.
4. Herbay AV, Herfarth C, Otto H. Cancer and dysplasia in ulcerative colitis: a histologic study of 301 surgical specimens. Z Gastroenterol 1994;32:382-8.
5. Bown S, Lovat LB. The biology of photodynamic therapy in the gastrointestinal tract. Gastrointest Endosc Clin North Am 2000;10:533-50.
6. Messmann H. Fluorescence endoscopy in gastroenterology. Z Gastroenterol 2000;38:21-30.
7. Messmann H. 5-Aminolevulinic acid-induced protoporphyrin IX for the detection of gastrointestinal dysplasia. Gastrointest Endosc Clin N Am 2000;10:497-512.
8. Bermudez Moretti M, Correa Garcia S, Stella C, Ramos E, Battle AM. Delta-aminolevulinic acid transport in Saccharomyces cerevisiae. Int J Biochem 1993;25:1917-20.
9. El-Sharabasy MM, el-Waseef AM, Hafez MM, Salim SA. Porphyrin metabolism in some malignant diseases. Br J Cancer 1992;65:409-12.
10. Hinnen P, de Rooij FW, van Velthuysen ML, Edixhoven A, van Hillegersberg R, Tilanus HW, et al. Biochemical basis of 5-aminolaevulinic acid-induced protoporphyrin IX accumulation: a study in patients with (pre)malignant lesions of the oesophagus. Br J Cancer 1998;78:679-82.
11. Kennedy JC, Pottier RH, Pross DC. Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience. J Photochem Photobiol 1990;6:143-8. Lasers Med Sci 1996;11:11-7.
12. Regula J, MacRobert AJ, Gorchein A. Photosensitization and photodynamic therapy of oesophageal, duodenal, and colorectal tumours using 5 aminolaevulinic acid induced protoporphyrin IX - a pilot study. Gut 1995;36:67-75.
13. Endlicher E, Knüchel R, Schölmerich J, Messmann H. Photodynamic diagnosis of dysplasia in longstanding ulcerative colitis after sensitization with 5-aminolevulinic acid. Gastrointest Endosc 1999;49:AB117.
14. Endlicher E, Knuechel R, Hauser T, Szeimies RM, Schölmerich J, Messmann H. Endoscopic fluorescence detection of low and high grade dysplasia in Barrett's oesophagus using systemic or local 5-aminolaevulinic acid sensitisation. Gut 2001;48:314-9.
15. Vo-Dinh T, Panjehpour M, Overholt BF, Farris C, Buckley FP 3rd, Sneed R. In vivo cancer diagnosis of the esophagus using differential normalized fluorescence (DNF) indices. Laser Surg Med 1995;16:41-7.
16. Panjehpour M, Overholt BF, Schmidhammer JL, Farris C, Buckley PF, Vo-Dinh T. Spectroscopic diagnosis of esophageal cancer: new classification model, improved measurement system. Gastrointest Endosc 1995;41:577-81.
17. Panjehpour M, Overholt BF, Vo-Dinh T, Haggitt RC, Edwards DH, Buckley FP 3rd. Endoscopic fluorescence detection of high-grade dysplasia in Barrett's esophagus. Gastroenterology 1996;111:93-101.
18. Stael von Holstein CS, Nilsson AM, Andersson-Engels S, Willen R, Walther B, Svanberg K. Detection of adenocarcinoma in Barrett's oesophagus by means of laser induced fluorescence. Gut 1996;39:711-6.
19. Kapadia CR, Cutruzzola FW, O'Brien KM, Stetz ML, Enriquez R, Deckelbaum LI. Laser-induced fluorescence spectroscopy of human colonic mucosa. Gastroenterology 1990;99:150-7.
20. Cothren RM, Richards-Kortum R, Sivak MV Jr, Fitzmaurice M, Rava RP, Boyce GA, et al. Gastrointestinal tissue diagnosis by laser-induced fluorescence spectroscopy at endoscopy. Gastrointest Endosc 1990;36:105-11.
21. Schomacker KT, Frisoli JK, Compton CC, Flotte TJ, Richter JM, Deutsch TF, et al. Ultraviolet laser-induced fluorescence of colonic polyps. Gastroenterology 1992;102:1155-60.
22. Eker C, Montan S, Jaramillo E, Koizumi K, Rubio C, Andersson-Engels S, et al. Clinical spectral characterisation of colonic mucosal lesions using autofluorescence and delta aminolaevulinic acid sensitisation. Gut 1999;44:511-8.
23. Messmann H, Kullmann F, Wild T, Knüchel-Clarke R, Rüschoff J, Gross V, et al. Detection of dysplastic lesions by fluorescence in a model of colitis in rats after previous photosensitization with 5-aminolaevulinic acid. Endoscopy 1998;30:333-8.
24. Gossner L, Stepp H, Sroka R, May A, Stolte M, Ell C. Photodynamic diagnosis (PDD) of high-grade dysplasia and early cancer in Barrett's esophagus using 5-aminolevulinic acid (ALA). Gastroenterology 1998;114:A136.
25. Haringsma J. Tytgat GNJ. Light-induced fluorescence endoscopy (LIFE) for the in vivo detection of colorectal dysplasia. Gastroenterology 1998;114:A606.
26. Heier SK, Rothman KA, Heier LM, Rosenthal WS. Photodynamic therapy for obstructing esophageal cancer. Light dosimetry and randomized comparison with Nd:YAG laser therapy. Gastroenterology 1995;109:63-72.
27. Messmann H, Holstege A, Szeimies RM, Lock G, Bown SG, Schölmerich J. Photodynamic therapy: a safe and effective treatment for tumor overgrowth in patients with esophageal cancer and metal stents. Endoscopy 1995;27:629.
28. Lightdale CJ, Heier SK, Marcon NE, McCaughan JS, Gerdes H, Overholt BF, et al. Photodynamic therapy with porfimer sodium versus thermal ablation therapy with Nd: YAG laser for palliation of esophageal cancer. Multicenter randomized trial. Gastrointest Endosc 1995;42:507-12.
29. Sibille A, Lambert R, Souquet JC, Sabben G, Descos F. Long-term survival after photodynamic therapy for esophageal cancer. Gastroenterology 1995;108:337-44.
30. Tian ME, Qui SL, Ki Q. Preliminary results of hematoporphyrin derivative-laser treatment for 13 cases of early esophageal carcinoma. Adv Exp Med Biol 1985;193:21-5.
31. Fujimaki M, Nakayama K. Endoscopic treatment of superficial esophageal cancer. Semi Surg Oncol 1986;2:248-56.
32. Tajiri H, Daikuzono M, Joffe SN. Photoradiation therapy in early gastrointestinal cancer. Gastrointest Endosc 1987;33:88-90.
33. Hayata Y, Kato H, Konaka C. Laser endoscopy in photodynamic therapy. Chirurgie 1988;59:81-9.
34. Okunata T, Kato H, Konaka C. Photodynamic therapy of esophageal carcinoma. Surg Endosc 1990;4:150-3.
35. Calzavara F, Tomio L, Corti L. Oesophageal cancer treated by photodynamic therapy alone or followed by radiation therapy. J Photochem Photobiol B 1990;6:167-74.
36. Grosjean P, Wagniéres G, Fontolliet C. Clinical photodynamic therapy for superficial cancer in the oesophagus and the bronchi: 514 nm compared with 630 nm light irradiation after sensitization with Photofrin II. Br J Cancer 1996;77:1989-95.
37. Messmann H, Szeimies RM, Bäumler W, Knüchel R, Zirngibl H, Schölmerich J, et al. Enhanced effectiveness of photodynamic therapy with laser light fractionation in patients with esophageal cancer. Endoscopy 1997;29:275-80.
38. Savary JF, Grosjean P, Monnier P, Fontolliet C, Wagnieres G, Braichotte D, et al. Photodynamic therapy of early squamous cell carcinomas of the esophagus: a review of 31 cases. Endoscopy 1998;30:258-65.
39. Barr H, Shepherd NA, Roberts DJH, Tan WC, Krasner N. Eradication of high-grade dysplasia in columnar-lined (Barrett's) oesophagus by photodynamic therapy with endogenously generated protoporphyrin IX. Lancet 1996;348:584-5.
40. Gossner L, Stolte M, Sroka R, Rick K, May A, Hahn EG, Ell C. Photodynamic ablation of high-grade dysplasia and early cancer in Barrett's esophagus by means of 5-aminolevulinic acid. Gastroenterology 1998;114:448-55.
41. Ackroyd R, Brown NJ, Davis MF, Stephenson TJ, Marcus SL, Stoddard CJ, et al. Photodynamic therapy for dysplastic Barrett's oesophagus: a prospective, double blind, randomised, placebo controlled trial. Gut 2000;47:612-7.
42. Wang KK. Current status of photodynamic therapy of Barrett's esophagus. Gastrointest Endosc 1999;49:S20.
43. Overholt BF, Panjepour M, Haydek JM. Photodynamic therapy for Barrett's esophagus: follow-up in 100 patients. Gastrointest Endosc 1999;49:1-7.
44. Overholt BF, Panjehpour M, Haydek JM. Photodynamic therapy (PD) for Barrett's esophagus with dysplasia: long term results. Gastrointest Endosc 2001;53:AB73.
45. Beejay U, Ribeiro A, Hourigan L, De la Mora G. Photodynamic therapy of high grade dysplasia/intramucosal carcinoma in Barrett's esophagus - 30 months follow-up. Gastrointest Endosc 2001;53:AB144.
46. Panjehpour M, Overholt BF, Haydek JM, Lee SG. Results of photodynamic therapy for ablation of dysplasia and early cancer in Barrett's esophagus and effect of oral steroids on stricture formation. Am J Gastroenterol 2000;95:2177-84.
47. Overholt BF, Haggitt RC, Bronner MP, Taylor SL, Hao Y, Colin P, et al. A multicenter, partially blinded, randomized study of the efficacy of photodynamic therapy (PDT) using porfimer sodium (POR) for the ablation of high grade dysplasia (HGD) in Barrett's esophagus (BE): Results of 6 month follow up. Gastroenterology 2001;120(Suppl 1):A79.
48. McCaughan JS Jr, Mertens BF, Cho C, Barabash RD, Payton HW. Photodynamic therapy to treat tumors of the extrahepatic biliary ducts. A case report. Arch Surg 1991;126:111-3.
49. Ortner MA, Liebetruth J, Schreiber S, Hanft M, Wruck U, Fusco V, et al. Photodynamic therapy of nonresectable cholangiocarcinoma. Gastroenterology 1998;114:536-42.
50. Ortner MA, Berr F, Liebetruth J, Giesse A, Caca K, Lochs H. Photodynamic therapy of non-resectable choangio carcinoma - a randomized prospective study - first results. Gastrointest Endosc 2001;53:AB85.
51. Berr F, Wiedmann M, Tannapfel A, Halm U, Kohlhaw KR, Schmidt F, et al. Photodynamic therapy for advanced bile duct cancer: evidence for improved palliation and extended survival. Hepatology 2000;31:291-8.
52. Mimura S. Long-term survival after photodynamic therapy with Photofrin® for early gastric cancer. IPA 8th World Congress of Photodynamic Medicine Vancouver 2001 (oral presentation).
53. Ell C, Gossner L, May A, Schneider HT, Hahn EG, Stolte M, et al. Photodynamic ablation of early cancers of the stomach by means of mTHPC and laser irradiation: preliminary clinical experience. Gut 1998;43:345-9.
54. Regula J, Ravi B, Bedwell J, MacRobert AJ, Bown SG. Photodynamic therapy using 5-aminolaevulinic acid for experimental pancreatic cancer - prolonged animal survival. Br J Cancer 1994;70:248-54.
55. Bown SG, Rogowska AZ, Whitelaw DE, Lees WR, Lovat LB, Ripley P, et al. Photodynamic therapy for cancer of the pancreas. Gut 2002 in press.
56. Messmann H, Mlkvy P, Buonaccorsi G, Davies CL, MacRobert AJ, Bown SG. Enhancement of photodynamic therapy with 5-aminolaevulinic acid-induced porphyrin photosensitisation in normal rat colon by threshold and light fractionation studies. Br J Cancer 1995;72:589-94.
57. Messmann H, Geisler M, Gross U, Abels C, Szeimies RM, Steinbach P, et al. Influence of a haematoporphyrin derivative on the protoporphyrin IX synthesis and photodynamic effect after 5-aminolaevulinic acid sensitization in human colon carcinoma cells. Br J Cancer 1997;76:878-83.
58. Gaullier JM, Berg K, Peng Q, Anholt H, Selbo PK, Ma LW, et al. Use of 5-aminolaevulinic acid esters to improve photodynamic therapy on cells in culture. Cancer Res 1997;57:1481-6.
59. Brunner H, Hausmann F, Krieg RC, Endlicher E, Schölmerich J, Knüchel R, et al. The effects of 5-aminolevulinic acid esters on protoporphyrin IX production in human adenocarcinoma cell lines. Photochem Photobiol 2001;74:721-5.
60. Lange N, Jichlinski P, Zellweger M, Forrer M, Marti A, Guillou L, et al. Photodetection of early human bladder cancer based on the fluorescence of 5-aminolaevulinic acid hexylester-induced protoporphyrin IX: a pilot study. Br J Cancer 1999;80:185-93.
61. Endlicher E, Rümmele P, Hausmann F, Krieg R, Knüchel R, Rath HC, et al. Protoporphyrin IX distribution following local application of 5-aminolaevulinic acid and its esterified derivatives in the tissue layers of the normal rat colon. Br J Cancer 2001;85:1572-6.